Prot #CACZ885U2301: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-Based Doublet Chemotherapy with or without Canakinumab as First Line Therapy for Locally Advanced or Met

Project: Research project

Project Details

StatusActive
Effective start/end date5/20/196/1/23

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CACZ885U2301)